NEW HAVEN, Conn., March 7, 2016 /PRNewswire/ -- Lucerne Biosciences, LLC announced today that on Friday evening EST last week it received two "bcc emails" minutes apart from Matsuman709@yahoo.com having the subject "a lead for you on a big financial story." The emails, identical in their content, were sent "to" financial journalists Nils Pratley of The Guardian and Jim Puzzanghera of the Los Angeles Times. Their opening paragraph states, "Consider me an informant for a very big financial story actively unfolding publicly but having no coverage because it is unprecedented in its nature and no journalist familiar with it seems to have the journalistic bandwidth to handle it. This is why I am providing you this lead. You are among a small group of broadly-skilled financial journalists I am contacting because your publications show you have the experience and knowledge to understand a story of this breadth and also to write about it, if you so choose. I am very familiar with the story but I am not giving you my name in order to protect my real identity. This story is essentially a 'whistleblower story' of unprecedented scope and I don't want to be in the middle of it. However, the public-at-large needs to learn about it, preferably from a skilled, credible and objective third-party journalist like you."
Lucerne Biosciences would like to ask the global public-at-large to provide the company feedback to the question: Who is "email@example.com the informant"?
The emails' last paragraph begins with, "If this story interests you, I can provide you some inside information (a document from today) to help you …..?" The company's follow-up question to the global public-at-large is: what in the world could this "whistleblower inside information" be all about?
The last paragraph of the two firstname.lastname@example.org emails concludes with, "Whatever is going on, it's clearly an intriguing story and looks ready to grab the attention of the public through some kind of 'final resolution.' For all I know, you [Nils Pratley or Jim Puzzanghera] and I [Matsuman709@yahoo.com] may even be a part of it." Lucerne Biosciences would like to publicly inform Matsuman709@yahoo.com, as well as Nils Pratley/The Guardian and Jim Puzzanghera/Los Angeles Times, that it wholly agrees with Matsuman709's view.
Any responses to the above questions are welcome and best made by email to email@example.com.
Additional Information/Related References
"The Patent '813 Story, Part II" (updated March 6, 2016 at 10 pm EST) available at: https://app.box.com/s/cgwi0xve5oidc5uu4vk7rk2vttbxb2g3 or at: http://www.4shared.com/download/W-ezclyvba/The_Patent_813_Story_Part_II_-.pdf?sbsr=80338958c604cba5a673d4c6bf5c1d8f969&lgfp=3000
Lucerne Biosciences Takes Business to New Haven, Connecticut, Bolstered by APS Holding Global Marketing Agreement of "The Patent '813 Story" (March 3, 2016) available at: http://www.prnewswire.com/news-releases/lucerne-biosciences-takes-business-to-new-haven-connecticut-bolstered-by-aps-holding-global-marketing-agreement-of-the-patent-813-story-300230207.html or in PDF at: https://app.box.com/s/d8g224suf7fz254r3745vm4s9sjemjqj
Louis Sanfilippo, Public Manager
Lucerne Biosciences, LLC
SOURCE Lucerne Biosciences, LLC